AstraZeneca, EU reach Covid vaccine supply settlement

The European Union (EU) and AstraZeneca (AZ) have reached an agreement that provides the delivery of AZ’s Vaxzevria Covid-19 vaccine doses to member states, per the terms of the Advance Purchase Agreement that ended on Aug. 27, 2020. The agreement between both parties also concludes the pending litigation before the Brussels Court.

The settlement agreement references AstraZeneca to deliver, in addition to the around 100 million doses delivered until the end of Q2, 135 million doses by the end of 2021 (60 million doses by the end of Q3 and 75 million doses by the end of Q4) and the remaining doses (65 million) by the end of March 2022, bringing the total number of supplied doses to 300 million.

EU member states will be provided with regular delivery schedules—if there are delayed doses, capped rebates will be put in place.

“… While this week we reached the important milestone of 70% full vaccination of the EU's adult population, there are significant differences in vaccination rates between our member states, and the continued availability of vaccines, including AstraZeneca's, remain crucial,” says Stella Kyriakides, EU’s commissioner for health and food safety. “… Our aim is to share at least 200 million doses of vaccines through COVAX with low and middle-income countries until the end of this year. Vaccine solidarity is and remains our trademark."